{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973216",
  "id": "02973216",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6fclzdgq5q2.pdf",
  "summary": "**Capital Raising Announcement Summary:**  \n- **Structure:** Institutional Placement  \n- **Total Capital Raised:** AUD 203 million  \n- **Issue Price:** AUD 4.20/share (2.2% premium to last close, 18.0% premium to 15-day VWAP).  \n- **Settlement Date:** 31 July 2025; **Listing Date:** 1 August 2025.  \n- **Pro-Forma Cash Balance:** AUD 288 million (post-placement).  \n\n**Key Upcoming Catalysts:**  \n- **Prostate Cancer Trials:**  \n  - Co-PSMA trial readout (Q3/Q4 2025).  \n  - Phase 3 trials (AMPLIFY/CLARIFY) completion (Q4 2025/H1 2026).  \n- **Regulatory Milestones:** NDA submission planning for 64Cu-SAR-bisPSMA.  \n- **Pipeline Progress:** First-in-human trials for breast cancer (64/67Cu-SAR-trastuzumab) and 64Cu-SAR-bisFAP (H2 2026).  \n\n**Additional Material Note:**  \n- Short interest in CU6 shares reached ~10% pre-placement.",
  "usage": {
    "prompt_tokens": 2623,
    "completion_tokens": 258,
    "total_tokens": 2881,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:50:09.568840"
}